Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2986]

'Labyrinth' chip could help monitor aggressive cancer stem cells

'Labyrinth' chip could help monitor aggressive cancer stem cells

Drug combination may improve impact of immunotherapy in head and neck cancer

Drug combination may improve impact of immunotherapy in head and neck cancer

Surgeons have major influence on breast cancer treatment

Surgeons have major influence on breast cancer treatment

Savings less than expected for generic oral chemotherapy

Savings less than expected for generic oral chemotherapy

ESMO 2017: EAPM roundtable at ESMO Congress on education, innovation and beyond

ESMO 2017: EAPM roundtable at ESMO Congress on education, innovation and beyond

ESMO 2017: Combined lenvatinib and pembrolizumab produces notable response rates in advanced renal carcinoma

ESMO 2017: Combined lenvatinib and pembrolizumab produces notable response rates in advanced renal carcinoma

ESMO 2017: Cancer patients struggle with key aspects of clinical trials

ESMO 2017: Cancer patients struggle with key aspects of clinical trials

ESMO 2017: Study shows ESMO Magnitude of Benefit Scale can be used to grade orphan drugs

ESMO 2017: Study shows ESMO Magnitude of Benefit Scale can be used to grade orphan drugs

European Alliance for Personalised Medicine discusses historic FDA approval for CAR T-cell therapy

European Alliance for Personalised Medicine discusses historic FDA approval for CAR T-cell therapy

ESMO 2017: Promising response rate to pembrolizumab in pretreated metastatic gastric cancer

ESMO 2017: Promising response rate to pembrolizumab in pretreated metastatic gastric cancer

More from ecancer